Evidence map›Paper›PMID 42059012›Full record

ArticleJournal of hepatocellular carcinoma2026

Safety and Efficacy of TACE-HAIC Combined with Lenvatinib and PD-1 Inhibitors in Large Intermediate-Stage Hepatocellular Carcinoma: A Multi-Center Retrospective Study.

Jiayan Ni, Chengzhi Li, Hongliang Sun, Yulong Liu, Gefan Guo, Xiong Zhou, Zhiyong Zhou, Rui Fan, Hao Hu, Linfeng Xu

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of hepatocellular carcinoma, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Jiayan Ni *Guangdong Provincial Key Laboratory of Malignant Tumor Epigenetics and Gene Regulation, Department of Interventional Radiology, Sun Yat-Sen Memorial Hospital, Sun Yat-Sen University, Guangzhou, People's Republic of China.ORCID 0000-0002-1502-9354
Chengzhi Li *Department of Interventional Radiology and Vascular Surgery, The First Affiliated Hospital of Jinan University, Guangzhou, People's Republic of China.
Hongliang SunGuangdong Provincial Key Laboratory of Malignant Tumor Epigenetics and Gene Regulation, Department of Interventional Radiology, Sun Yat-Sen Memorial Hospital, Sun Yat-Sen University, Guangzhou, People's Republic of China.
Yulong LiuDepartment of Interventional Radiology and Vascular Surgery, The First Affiliated Hospital of Jinan University, Guangzhou, People's Republic of China.
Gefan GuoGuangdong Provincial Key Laboratory of Malignant Tumor Epigenetics and Gene Regulation, Department of Interventional Radiology, Sun Yat-Sen Memorial Hospital, Sun Yat-Sen University, Guangzhou, People's Republic of China.
Xiong ZhouDepartment of Interventional Radiology, Shenshan Medical Center, Memorial Hospital of Sun Yat-Sen University, Shanwei, People's Republic of China.
Zhiyong ZhouGuangdong Provincial Key Laboratory of Malignant Tumor Epigenetics and Gene Regulation, Department of Interventional Radiology, Sun Yat-Sen Memorial Hospital, Sun Yat-Sen University, Guangzhou, People's Republic of China.
Rui FanGuangdong Provincial Key Laboratory of Malignant Tumor Epigenetics and Gene Regulation, Department of Interventional Radiology, Sun Yat-Sen Memorial Hospital, Sun Yat-Sen University, Guangzhou, People's Republic of China.
Hao HuInterventional Department, The Fourth People's Hospital of Zigong, Zigong, People's Republic of China.
Linfeng XuGuangdong Provincial Key Laboratory of Malignant Tumor Epigenetics and Gene Regulation, Department of Interventional Radiology, Sun Yat-Sen Memorial Hospital, Sun Yat-Sen University, Guangzhou, People's Republic of China.ORCID 0000-0002-4217-328X

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Purpose: This study was designed to compare the safety and efficacy of transarterial chemoembolization (TACE) plus hepatic arterial infusion chemotherapy (HAIC) or TACE combined with lenvatinib (LEN) and PD-1 inhibitors (PD-1i) in large intermediate-stage hepatocellular carcinoma (iHCC). Methods: This multi-center retrospective study was conducted at four tertiary medical centers. From January 01, 2021, to June 30, 2024, 221 patients with large iHCC undergoing TACE-HAIC-LEN-PD-1i (THLP group, n=103) or TACE-LEN-PD-1i (TLP group, n=118) were enrolled. Local tumor responses, survival, and treatment-related adverse events (TRAEs) were analyzed between the THLP and TLP groups. Results: Baseline characteristics were well-balanced between the two groups ( Conclusion: TACE-HAIC-LEN-PD-1i was safe and well-tolerated, and achieved better efficacy than TACE-LEN-PD-1i in patients with large iHCC. Further randomized controlled trials are required to validate the benefits of TACE-HAIC-LEN-PD-1i.

Indexed as

hepatic arterial infusion chemotherapyhepatocellular carcinomaimmune checkpoint inhibitortransarterial chemoembolizationtyrosine kinase inhibitor

Identifiers

PMID42059012
PMCPMC13123561

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.